Q3 EPS Estimates for Exact Sciences Boosted by William Blair

Key Points

• William Blair has raised its Q3 2025 earnings per share estimate for Exact Sciences from $0.11 to $0.13, while also providing projections for Q1-Q3 2026 and full-year 2026 earnings.
• Despite improving estimates, several analysts have adjusted their target prices downward, with Royal Bank Of Canada lowering theirs to $46 and Barclays to $55, reflecting a cautionary outlook on the stock.
• Exact Sciences reported a strong Q2 with an EPS of $0.22, exceeding expectations and showing a 16% increase in quarterly revenue year-over-year.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Equities researchers at William Blair boosted their Q3 2025 earnings per share estimates for Exact Sciences in a research report issued on Wednesday, September 10th. William Blair analyst A. Brackmann now forecasts that the medical research company will earn $0.13 per share for the quarter, up from their prior estimate of $0.11. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences' Q1 2026 earnings at $0.14 EPS, Q2 2026 earnings at $0.30 EPS, Q3 2026 earnings at $0.33 EPS and FY2026 earnings at $1.13 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm had revenue of $811.09 million during the quarter, compared to analyst estimates of $774.43 million. During the same quarter in the prior year, the firm earned ($0.09) EPS. The business's revenue for the quarter was up 16.0% compared to the same quarter last year.

EXAS has been the subject of several other reports. Cowen reissued a "buy" rating on shares of Exact Sciences in a report on Thursday, August 7th. Craig Hallum increased their target price on Exact Sciences from $65.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, September 11th. Zacks Research cut shares of Exact Sciences from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 4th. UBS Group cut their price target on Exact Sciences from $61.00 to $53.00 and set a "neutral" rating for the company in a report on Thursday, August 7th. Finally, Royal Bank Of Canada dropped their price target on Exact Sciences from $54.00 to $46.00 and set a "sector perform" rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $68.05.

Exact Sciences Stock Performance

EXAS traded down $0.05 during midday trading on Friday, reaching $52.89. The company had a trading volume of 708,135 shares, compared to its average volume of 2,790,903. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The business has a 50-day moving average of $48.87 and a two-hundred day moving average of $49.36. The company has a market cap of $10.01 billion, a P/E ratio of -9.74, a P/E/G ratio of 4.93 and a beta of 1.05. Exact Sciences has a 1 year low of $38.81 and a 1 year high of $72.83.

Insider Buying and Selling at Exact Sciences

In other news, Director James Edward Doyle sold 1,485 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $42.02, for a total value of $62,399.70. Following the completion of the sale, the director owned 59,962 shares of the company's stock, valued at approximately $2,519,603.24. This represents a 2.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.

Institutional Trading of Exact Sciences

A number of hedge funds have recently bought and sold shares of EXAS. Massachusetts Financial Services Co. MA purchased a new stake in shares of Exact Sciences during the 2nd quarter worth $157,805,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Exact Sciences by 120.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company's stock valued at $135,453,000 after buying an additional 1,707,287 shares during the last quarter. Mackenzie Financial Corp lifted its position in shares of Exact Sciences by 107.7% during the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company's stock valued at $164,037,000 after buying an additional 1,513,873 shares during the last quarter. Holocene Advisors LP lifted its position in shares of Exact Sciences by 189.5% during the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company's stock valued at $113,995,000 after buying an additional 1,404,086 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Exact Sciences during the first quarter valued at about $45,334,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.